Methoxypolyethylene glycol epoetin beta
Methoxypolyethylene Glycol Epoetin Beta
Methoxypolyethylene glycol epoetin beta, also known as CERA (Continuous Erythropoietin Receptor Activator), is a long-acting erythropoiesis-stimulating agent (ESA) used in the treatment of anemia associated with chronic kidney disease (CKD). It is a chemically modified form of erythropoietin, a hormone that stimulates the production of red blood cells.
Mechanism of Action[edit | edit source]
Methoxypolyethylene glycol epoetin beta works by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating the production of red blood cells. The addition of a methoxypolyethylene glycol (PEG) chain increases the molecule's size and stability, allowing for a prolonged half-life and less frequent dosing compared to traditional erythropoietin.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of methoxypolyethylene glycol epoetin beta are characterized by a long half-life, which allows for administration at extended intervals, typically once every two to four weeks. This is in contrast to other ESAs, which may require more frequent dosing. The PEGylation of the molecule reduces renal clearance and increases its duration of action.
Clinical Use[edit | edit source]
Methoxypolyethylene glycol epoetin beta is primarily used to treat anemia in patients with chronic kidney disease, both in those undergoing dialysis and those not on dialysis. It helps to reduce the need for blood transfusions and improve quality of life by increasing hemoglobin levels.
Side Effects[edit | edit source]
Common side effects of methoxypolyethylene glycol epoetin beta include hypertension, headache, joint pain, and injection site reactions. Serious side effects may include thromboembolic events, such as deep vein thrombosis and pulmonary embolism, particularly if hemoglobin levels are raised too high.
Regulatory Status[edit | edit source]
Methoxypolyethylene glycol epoetin beta is approved for use in several countries, including the United States and European Union, for the treatment of anemia associated with chronic kidney disease. It is marketed under various brand names, including Mircera.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Bonnu, Prab R. Tumpati, MD
